464 related articles for article (PubMed ID: 15800317)
1. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
7. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
[TBL] [Abstract][Full Text] [Related]
9. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
10. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
11. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
19. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
